Competition 25 – Women’s health

Key Features

SBRI Healthcare provides a mechanism to signal the challenges that the NHS and the wider system face and invites entrepreneurs to deploy innovative solutions to deliver improved outcomes of care and efficiencies.

Programme:     SBRI

Award:     Share of up to £800,000

Opens: 17th Jul 2024

Closes: 28th Aug 2024

! This scheme is now closed

Overview

SBRI Healthcare provides a mechanism to signal the challenges that the NHS and the wider system face and invites entrepreneurs to deploy innovative solutions to deliver improved outcomes of care and efficiencies in women’s health. Our individual competition themes are scoped by working in close collaboration with the Health Innovation Network and frontline NHS and social care staff.

At early stage, the SBRI Healthcare programme offers a two-phased development approach; projects start with initial feasibility and subject to funding can then move on to more detailed product development. Phase 1 contracts for technical and commercial feasibility testing are valued at up to £100,000 (NET) and last for six months. Phase 2 contracts for prototype development and early clinical evidence are worth up to £800,000 (NET), subject to budget availability, over one year.

Scope

The SBRI Healthcare Competition 25 Phase 1 funding competition invites breakthrough technologies to address challenges in Women’s Health and aims to identify innovative solutions which have the potential to enter the NHS, social care and the wider market, tackling:

1. Gynaecological Conditions and Hormonal Health
2. Mental Health
3. Chronic Conditions and Long-term Health

Applicants are asked to consider the impact of their innovation on the whole system and to be aware of the competitive environment, even considering working together with other companies and organisations to bring forward solutions that can make a real difference. Solutions which address any challenges associated with health inequalities, such as demographic and geographic disparities, and show a strong commitment to contribute to the NHS carbon reduction ambitions are particularly welcomed.

The SBRI Healthcare Phase 1 funding competition invites outstanding entrepreneurs to put forward breakthrough innovations which address a clearly articulated challenge faced by the NHS and/or the social care community. The aim of the open tender is to facilitate the development and validation of such innovations and build on the value proposition required by commissioners and regulators for NHS adoption and wider commercialisation.

Phase 1 proposals concentrate on activities which will significantly contribute to proving the technical and commercial feasibility of the proposed innovation. If successful at Phase 1, and subject to budget availability, projects are eligible to apply for further funding at Phase 2, which will allow teams to undertake prototype development and generate clinical evidence. At the end of Phase 2, it is intended that the proposed solution will be ready for the next stage of development (e.g., manufacturing, regulatory approvals, etc), NHS adoption and/or wider commercialisation.

Challenges

Applicants are expected to respond to one or more of the categories and should consider if their solution is specific to or can be tailored to one of the categories, whilst being mindful of the broader impact.

In line with national strategies and reports, this funding competition seeks innovative solutions to improve Women’s Health outcomes. Emphasis will be placed on addressing the needs of marginalized and underserved populations, including women from ethnic minority communities, those facing socioeconomic challenges, individuals with disabilities, and other vulnerable groups.

Care pathways run from awareness of a health issue to access to services and preventive care, timely and accurate diagnosis and effective treatment and follow-up. At each segment of individual pathways, inequalities exist, especially for women who are disadvantaged in ways beyond their gender. Under the overall theme of “Women’s Health”, the following 3 sub-challenges have been identified:

• Gynaecological Conditions and Hormonal Health
• Mental Health
• Chronic Conditions and Long-term Health

Bidders must be cognizant that female life course and associated problems (menarche-puberty, fertility, menopause, older adulthood etc) are strongly linked. Solutions that take a women’s centred and holistic approach, by demonstrating that female voices have been considered throughout the proposal (from problem definition to identification of solution), will be crucial.

Tools that increase awareness from healthcare personnel on how and when health conditions manifest in different subgroups of women, technologies that enable improved tracking and monitoring of health conditions and patient reported outcome measures and interventions that help women to self-manage and identify thresholds for care increase and access to screening programmes would be welcome across all the proposed challenges.

For further information on the challenge, please see here

Eligibility

The competition is open to single organisations (contracts are executed with individual legal entities) based in the UK or EU from the private, public, and third sectors, including companies (large corporates and small and medium enterprises), charities, universities and NHS providers, as long as a strong commercial strategy is provided. Organisations based outside the UK or EU with innovations in remit for this call can apply as  subcontractors of a lead UK/EU based organisation or via a UK or EU subsidiary.

Collaborations are encouraged in the form of subcontracted  services as appropriate.

Exclusions

There are a number of technologies or types of solutions which are already available or will not make a significant impact on the challenges addressed in this brief. These are listed below.

• Any technologies that negatively impact staff workloads and do not support the workforce pressure, or those that require high upfront capital investment by clinical services (therefore negatively impacting on NHS affordability) will be excluded.
• Systems and solutions that will not easily integrate or communicate with NHS/community setting systems.
• Technologies that will exacerbate health inequalities (including digital exclusion or data inequalities) and inequity of access to care e.g., digital technologies that are inaccessible to certain communities that experience digital poverty.
• Solutions that were not co-designed with women
• Solutions which do not recognise nor address the intersectionality of health determinants, including socioeconomic status, race, and gender identity, in managing
chronic conditions among women.
• Medicines.

Desirable exit points

At the end of Phase 1, projects are expected to have established the technical merit, feasibility, and commercial potential of the proposed technology.

Examples of exit points include:
• Feasibility technical study
• Market validation
• Business plan developed
• Clinical and/or social care partners identified
• Evidence generation plan for adoption
• Development of patient and public involvement and engagement (PPIE) strategy
• Development of net zero strategy to demonstrate environmental impact
• Health inequalities impact assessment

Following successful completion of Phase 1, projects can apply for further funding at Phase 2 to continue development, subject to budget availability. It is expected that at the end of Phase 2, some of the following will be achieved:

• Minimum viable product developed
• Early clinical evidence gathered to demonstrate safety and accuracy
• Developed commercialisation strategy
• Health economics
• Evidence gathered towards regulatory approval
• Implementation plan for adoption
• Strong involvement and engagement with patients and the public
• Projected carbon savings of the proposed innovation and methodology used to estimate the carbon impact
• Timeline and strategy to comply with the requirement set out in the NHS Supply Roadmap, including the development of a Carbon Reduction Plan
• Next stream of funding identified / investment readiness.

Funding Costs

This SBRI Healthcare competition is funded by the Accelerated Access Collaborative (AAC) in partnership with the Health Innovation Network to identify innovative new products and services. The projects will be selected primarily on their potential value to the health service and social care system and on the improved outcomes delivered for those in receipt of care.

The competition runs in two phases (subject to availability of budget in 2025/26):

• Phase 1 is intended to show the technical and commercial feasibility of the proposed concept. The development contracts will be for a maximum of 6 months and up to £100,000 (excl. VAT) per project.
• Phase 2 contracts are intended to develop and evaluate prototypes or demonstration units over a maximum of 12 months with up to £800,000 (excl. VAT). Only those projects
that have successfully completed Phase 1 will be eligible for Phase 2.

Projects will be 100% funded and suppliers for each project will be selected by an open competition process and retain the intellectual property rights (IPR) generated from the project, with certain rights of use retained by the NHS.

Interested in applying for this competition?

Book an appointment to speak to one of our advisors to discuss your eligibility to apply for this Grant Funding opportunity.